Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1 13Phase 1/2 12Phase NA 4Phase 3 2

Status

Completed 56Terminated 11Unknown 8Active not recruiting 6Recruiting 3Withdrawn 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Breast Neoplasms 25Neoplasms 19Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Pain 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lymphoma, Follicular 6Leukemia 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Non-Muscle Invasive Bladder Neoplasms 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leiomyoma 4Carcinoma 4Urologic Neoplasms 3Urogenital Neoplasms 3Papillomavirus Infections 3

Interventions

Tacrolimus 1Methotrexate 1Atorvastatin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Myelodysplastic Syndromes × Clear all
NCT03066466 2021-04-27

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

Loyola University

Phase 3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00226512 2011-04-08

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

Hadassah Medical Organization

Phase 3 Withdrawn
203 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡